This topic contains a solution. Click here to go to the answer

Author Question: Which bond would show a strong, sharp absorption in the IR between 1200 and 1000 cm1? A) OH B) ... (Read 17 times)

jake

  • Hero Member
  • *****
  • Posts: 538
Which bond would show a strong, sharp absorption in the IR between 1200 and 1000 cm1?
  A)
  OH
  B)
  NH
  C)
  C=O
  D)
  CH
  E)
  CO

Question 2

Which bond would show a sharp absorption in the IR between 3000 and 2800 cm1?
  A)
  OH
  B)
  NH
  C)
  C=O
  D)
  CH
  E)
  CO



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Viet Thy

  • Sr. Member
  • ****
  • Posts: 329
Answer to Question 1

e

Answer to Question 2

d




jake

  • Member
  • Posts: 538
Reply 2 on: Aug 23, 2018
Excellent


momolu

  • Member
  • Posts: 320
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

An identified risk factor for osteoporosis is the intake of excessive amounts of vitamin A. Dietary intake of approximately double the recommended daily amount of vitamin A, by women, has been shown to reduce bone mineral density and increase the chances for hip fractures compared with women who consumed the recommended daily amount (or less) of vitamin A.

Did you know?

Side effects from substance abuse include nausea, dehydration, reduced productivitiy, and dependence. Though these effects usually worsen over time, the constant need for the substance often overcomes rational thinking.

Did you know?

In 1886, William Bates reported on the discovery of a substance produced by the adrenal gland that turned out to be epinephrine (adrenaline). In 1904, this drug was first artificially synthesized by Friedrich Stolz.

Did you know?

Adult head lice are gray, about ? inch long, and often have a tiny dot on their backs. A female can lay between 50 and 150 eggs within the several weeks that she is alive. They feed on human blood.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library